KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021)

AbCellera Biologics' Receivables - Other history spans 2 years, with the latest figure at $62.1 million for Q2 2021.

  • For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $62.1 million, compared with a TTM value of $62.1 million through Jun 2021, changed N/A, and an annual FY2020 reading of $212.3 million, changed N/A over the prior year.
  • Receivables - Other for Q2 2021 was $62.1 million at AbCellera Biologics, down from $193.1 million in the prior quarter.
  • The five-year high for Receivables - Other was $212.3 million in Q4 2020, with the low at $62.1 million in Q2 2021.